Lilian J. A. Driessen-Engels

Statistics

Publications

Citations

329

H-Index

Active since

2012

Affiliations

Merck B.V. (Netherlands)(Current)

Lilian J. A. Driessen-Engels is an author at Merck B.V. (Netherlands) specializing in pd-l1 blockade, programmed death-1 blockade, and immuno-oncology biomarkers.

Publications per year

2012–2013

Publications

PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer

John Dulos, Gregory J. Carven, Susan J. van Boxtel et al. · Journal of Immunotherapy · 2012 · 318 citations

Life Sciences, Immunology, Oncology +17

In Vivo Knockdown of TAK1 Accelerates Bone Marrow Proliferation/Differentiation and Induces Systemic Inflammation

Paul Vink, Wendy M. Smout, Lilian J. A. Driessen-Engels et al. · PLoS ONE · 2013 · 11 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

1–2 of 2